glp-1 testing drugs carry wide variety of risks, benefits beyond weight loss The biomarkers to watch when
Description
Patients with bleeding disorders or those taking blood thinners should inform their provider about injection-site bleeding, though minor bleeding is not dangerous
The use of incretin mimetics is also recommended as add-on therapy in people with type 2 diabetes and obesity when initial therapy provides insufficient glycaemic control.
Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists
A.JohnsonJ
This can contribute to obesity, which is itself a risk factor for various health problems
